Stroke Market Report 2026

The stroke market size has grown rapidly in recent years. It will grow from $39.72 billion in 2025 to $43.91 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, aging population demographics, improved hospital stroke care infrastructure, wider availability of diagnostic imaging, increased public awareness of stroke symptoms.

The stroke market size is expected to see rapid growth in the next few years. It will grow to $64.75 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to expansion of AI-assisted clinical decision tools, rising investment in minimally invasive stroke treatments, growing adoption of remote stroke monitoring, increasing focus on preventive stroke care, expansion of advanced neurovascular devices. Major trends in the forecast period include increasing adoption of AI-based stroke diagnostics, rising use of thrombolytic and thrombectomy procedures, growing focus on rapid emergency response systems, expansion of tele-stroke networks, enhanced use of advanced neuroimaging.

The rising prevalence of hypertension is expected to drive the growth of the stroke market going forward. Hypertension, commonly referred to as high blood pressure, is a condition in which the force of blood against the artery walls remains consistently elevated. The increase in hypertension cases is primarily attributed to the growing rate of obesity, as excess body weight places additional strain on the heart and blood vessels, gradually leading to elevated blood pressure. Hypertension contributes to stroke by exerting excessive pressure on blood vessel walls, which can cause weakening, narrowing, or rupture of arteries in the brain. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based organization, high blood pressure was a primary or contributing factor in 664,470 deaths in the United States in 2023. Therefore, the rising prevalence of hypertension is fueling the growth of the stroke market.

Major companies operating in the stroke market are focusing on developing innovative stroke intervention devices, such as flow-regulated large-bore access catheters, to improve procedural precision and enhance outcomes in complex neurovascular interventions like mechanical thrombectomy. Flow-regulated large-bore access refers to a catheter design that combines a wide inner diameter for device delivery with integrated blood flow control, enabling safer and more effective navigation during neurovascular procedures. For instance, in February 2025, Johnson & Johnson MedTech, a US-based medical technology company, launched the CEREGLIDE 92 Catheter System, a next-generation 0.092” catheter that enhances access and flow control during mechanical thrombectomy for acute ischemic stroke. The system helps clinicians navigate brain anatomy and restore blood flow more effectively. It features the INNERGLIDE 9 delivery aid for smooth catheter insertion, BRITE-LINE technology for improved procedural visibility, and a TruCourse flexible tip for better navigation through complex brain vessels. Additionally, it supports sustainability through electronic instructions for use, reducing environmental impact.

In May 2025, Merck KGaA, a US-based science and technology company, acquired ApTOLL from AptaTargets for an undisclosed amount. Through this acquisition, Merck KGaA aims to expand its neurology portfolio by advancing the development and commercialization of ApTOLL, a novel therapy targeting acute ischemic stroke with potential to reduce inflammation and brain damage, thereby improving patient outcomes. AptaTargets SL is a Spain-based biotechnology company specializing in novel therapies for acute neurological conditions, particularly acute ischemic stroke.

Major companies operating in the stroke market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Medtronic plc, Fresenius SE & Co. KGaA, Stryker Corporation, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals USA Inc., Daiichi Sankyo Company Limited, Amneal Pharmaceuticals LLC, Lupin Limited, MicroPort Scientific Corporation, Penumbra Inc., NeuroVasc Technologies Inc.

North America was the largest region in the stroke market in 2025, and it is expected to be the fastest-growing region in the forecast period. The regions covered in the stroke market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stroke market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the stroke market by increasing costs of imported neuroimaging equipment, catheters, stents, diagnostic software, and pharmaceutical products used in acute stroke diagnosis and treatment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported high-value medical devices, while Asia-Pacific faces cost pressures on device manufacturing and exports. These tariffs are elevating treatment costs and slowing technology upgrades. At the same time, they are encouraging domestic medical device production, regional manufacturing partnerships, and local innovation in stroke care technologies.

The stroke market research report is one of a series of new reports that provides stroke market statistics, including stroke industry global market size, regional shares, competitors with a stroke market share, detailed stroke market segments, market trends and opportunities, and any further data you may need to thrive in the stroke industry. This stroke market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stroke is a serious medical condition that occurs when the blood supply to part of the brain is interrupted or reduced, preventing brain tissue from receiving essential oxygen and nutrients. This disruption can lead to brain cell death within minutes, resulting in sudden loss of function such as difficulty speaking, paralysis, or impaired cognitive abilities, and may cause long-term disability or death if not treated promptly.

The primary types of stroke are ischemic stroke, transient ischemic attack (TIA), and hemorrhagic stroke. Ischemic stroke occurs when a blood clot or other obstruction blocks blood flow to the brain, depriving brain tissue of oxygen and nutrients. Stroke diagnosis and treatment are provided for various patient groups, including male and female patients, through multiple distribution channels such as direct, retail, and online services. These solutions are used by end users such as hospitals, clinics, and specialized stroke care centers.

The stroke market includes revenues earned by entities by providing services such as emergency medical services, imaging services, and blood pressure management. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.